SCHEMBL61209

SCHEMBL61209

CC1(C)C2CC[C@H](CCCC(=O)O)C1C2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 1/20 0.47
MAPK14 Q16539 1/20 0.47
CAMK1D Q8IU85 1/20 0.47
ALOX5 P09917 1/20 0.46
CDC25A P30304 1/20 0.41
HDAC6 Q9UBN7 3/20 0.40
S1PR1 P21453 1/20 0.39
EPHX2 P34913 1/20 0.38
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
OGFRL1 Q5TC84 1/20 0.38
UGT2B7 P16662 1/20 0.38
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
PTGDR Q13258 3/20 0.37
AR P10275 2/20 0.37
TBXA2R P21731 1/20 0.37
ALOX15 P16050 1/20 0.36
SCN9A Q15858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27033234 0.94 ALOX5 (0.47) RETMAPK14CAMK1DALOX5CDC25A
SCHEMBL11604288 0.90 RET (0.49) RETMAPK14CAMK1DALOX5HDAC6
SCHEMBL8991630 0.84 RET (0.40) RETMAPK14CAMK1DHDAC6S1PR1
SCHEMBL11604726 0.81 MAPK14 (0.50) RETMAPK14CAMK1DHDAC6S1PR1
SCHEMBL60332 0.81 RET (0.42) RETMAPK14CAMK1DHDAC6S1PR1
SCHEMBL1786883 0.80 RET (0.51) RETMAPK14CAMK1DCDC25AHDAC6
SCHEMBL3708800 0.80 RET (0.51) RETMAPK14CAMK1DCDC25AHDAC6
SCHEMBL1788714 0.80 RET (0.51) RETMAPK14CAMK1DCDC25AHDAC6
SCHEMBL1788712 0.80 RET (0.51) RETMAPK14CAMK1DCDC25AHDAC6
SCHEMBL3708801 0.80 RET (0.51) RETMAPK14CAMK1DCDC25AHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9446021-B2 Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof DOGWOOD PHARMACEUTICALS, INC. (US) 2016-09-20 US disclosed
US-20150313873-A1 Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof DOGWOOD PHARMACEUTICALS, INC. 2015-11-05 US disclosed
US-9120754-B2 Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof DOGWOOD PHARMACEUTICALS, INC. (US) 2015-09-01 US disclosed
US-20120129837-A1 Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof ALLERGAN SALES, LLC 2012-05-24 US disclosed
US-8129519-B2 Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof ALLERGAN SALES, LLC 2012-03-06 US disclosed
US-20100137354-A1 DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF ALLERGAN SALES, LLC 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129837-A1 Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof WNT1, CTNND1, CTNNB1 RET 1772/4885MAPK14 301/4885CAMK1D 3281/4885
US-20150313873-A1 Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof WNT1, CTNND1, CTNNB1 RET 1772/4885MAPK14 301/4885CAMK1D 3281/4885
US-20100137354-A1 DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF WNT1, CTNND1, CTNNB1 RET 1772/4885MAPK14 301/4885CAMK1D 3281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.